Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Capital Expenditures (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Capital Expenditures for 4 consecutive years, with $195000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Capital Expenditures changed N/A to $195000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $1.3 million, a N/A change, with the full-year FY2024 number at $154000.0, down 98.88% from a year prior.
  • Capital Expenditures was $195000.0 for Q3 2025 at Century Therapeutics, down from $317000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $29.4 million in Q4 2022 to a low of -$13.3 million in Q3 2022.
  • A 4-year average of $3.5 million and a median of $975000.0 in 2023 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: surged 124.57% in 2023, then plummeted 96.89% in 2024.
  • Century Therapeutics' Capital Expenditures stood at $29.4 million in 2022, then plummeted by 96.66% to $980000.0 in 2023, then tumbled by 72.96% to $265000.0 in 2024, then fell by 26.42% to $195000.0 in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Capital Expenditures are $195000.0 (Q3 2025), $317000.0 (Q2 2025), and $475000.0 (Q1 2025).